LLY241101P620000
- 0.03
- 0.000.00%
Eli Lilly and Co Newsroom
Earnings Miss: Eli Lilly and Company Missed EPS By 31% And Analysts Are Revising Their Forecasts
Roche's Antibody Against Alzheimer's Looks the Best Yet -- Barrons.com
AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com
Eli Lilly and Co Options Spot-On: On October 31st, 103.23K Contracts Were Traded, With 345.79K Open Interest
On October 31st ET, $Eli Lilly and Co(LLY.US)$ had active options trading, with a total trading volume of 103.23K options for the day, of which put options accounted for 42.0% of the total
Barclays Maintains Overweight on Eli Lilly, Lowers Price Target to $975
Eli Lilly 'Well-Positioned' for Growth Into 2025 Despite Q3 Volatility, UBS Says
Eli Lilly Earnings Have Wall Street Jittery on Zepbound Sales. What Comes Next. -- Barrons.com
Live On CNBC, Stephanie Link Announces Bought More Eli Lilly And Company
Biogen Slips as Morgan Stanley Downgrades on Leqembi Launch
Eli Lilly and Company (NYSE:LLY): Among The 10 Best S&P 500 Stocks to Buy According to Hedge Funds
Eli Lilly and Co's non-covalent BTK inhibitor approved in China, hot competition among domestic and foreign pharmaceutical companies for market layout.
The approval of Calquence brings a new option for Chinese MCL patients who have previously received covalent BTK therapy.
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $975 to $1,100
Eli Lilly Is Maintained at Buy by B of A Securities
Express News | Elektrofi Inc: Financing Led by Novo Holdings, Others With Participation From Eli Lilly and Company
Express News | Elektrofi Inc: Announces Oversubscribed $112.25 Mln Series C Financing
Eli Lilly Analyst Ratings
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Jefferies Adjusts Price Target on Eli Lilly to $994 From $1,113, Maintains Buy Rating
Express News | Eli Lilly & Co. : Morgan Stanley Cuts Target Price to $1146.00 From $1158.00
Nasdaq Tumbles Over 100 Points Ahead Of Big Tech Earnings: Fear & Greed Index Remains In 'Greed' Zone